Certara (NASDAQ:CERT) Shares Gap Up – Should You Buy?

Certara, Inc. (NASDAQ:CERT) shares gapped up prior to trading on Friday . The stock had previously closed at $14.25, but opened at $15.18. Certara shares last traded at $15.15, with a volume of 689,656 shares.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Barclays decreased their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Robert W. Baird dropped their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.92.

Certara Stock Up 2.3 %

The business has a 50-day moving average price of $12.03 and a 200-day moving average price of $11.73. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -72.95, a price-to-earnings-growth ratio of 9.33 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Venturi Wealth Management LLC grew its holdings in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN grew its stake in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares in the last quarter. Blue Trust Inc. grew its stake in Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after purchasing an additional 2,076 shares in the last quarter. KBC Group NV grew its stake in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its stake in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after purchasing an additional 3,656 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.